Department of Thoracic Surgery Unit II, Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, 52 Fucheng Road, Beijing, 100142, China.
Department of Cell Biology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, 52 Fucheng Road, Beijing, 100142, China.
Cell Death Dis. 2021 Mar 11;12(3):257. doi: 10.1038/s41419-021-03522-0.
It is hypothesized that tumor-initiating cells (TICs) with stem cell-like properties constitute a sustaining force to drive tumor growth and renew fully established malignancy. However, the identification of such a population in non-small cell lung carcinoma (NSCLC) has been hindered by the lacking of reliable surface markers, and very few of the currently available surface markers are of functional significance. Here, we demonstrate that a subpopulation of TICs could be specifically defined by the voltage-gated calcium channel α2δ1 subunit from non-small cell lung carcinoma (NSCLC) cell lines and clinical specimens. The α2δ1 NSCLC TICs are refractory to conventional chemotherapy, and own stem cell-like properties such as self-renewal, and the ability to generate heterogeneous tumors in NOD/SCID mice. Moreover, α2δ1 NSCLC cells are more enriched for TICs than CD133, or CD166 cells. Interestingly, α2δ1 is functionally sufficient and indispensable to promote TIC properties by mediating Ca influx into cells, which subsequently activate Calcineurin/NFATc2 signaling that directly activates the expression of NOTCH3, ABCG2. Importantly, a specific antibody against α2δ1 has remarkably therapeutic effects on NSCLC xenografts by eradicating TICs. Hence, targeting α2δ1 to prevent calcium influx provides a novel strategy for targeted therapy against TICs of NSCLC.
人们假设具有干细胞样特性的肿瘤起始细胞(TICs)构成了推动肿瘤生长和更新完全建立的恶性肿瘤的维持力量。然而,由于缺乏可靠的表面标志物,因此很难在非小细胞肺癌(NSCLC)中鉴定出这样的群体,而目前可用的少数表面标志物具有功能意义。在这里,我们证明了电压门控钙通道α2δ1 亚基可以从非小细胞肺癌(NSCLC)细胞系和临床标本中特异性定义 TIC 亚群。α2δ1 NSCLC TIC 对常规化疗具有抗药性,并且具有自我更新和在 NOD/SCID 小鼠中产生异质肿瘤的能力等干细胞样特性。此外,与 CD133 或 CD166 细胞相比,α2δ1 NSCLC 细胞中 TIC 更为丰富。有趣的是,α2δ1 通过将 Ca 内流介导到细胞中,从而激活 Calcineurin/NFATc2 信号,从而直接激活 NOTCH3、ABCG2 的表达,从而在功能上足以促进 TIC 特性,这是必不可少的。重要的是,针对α2δ1 的特异性抗体通过消除 TIC 对 NSCLC 异种移植物具有显著的治疗作用。因此,靶向α2δ1 以防止钙内流为针对 NSCLC 的 TIC 提供了一种新的靶向治疗策略。